Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
a study on End of Life Cancer, General
Summary
- Eligibility
- for people ages 21 years and up (full criteria)
- Location
- at UCSF
- Dates
- study startedcompletion around
Description
Summary
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
Details
PRIMARY OBJECTIVES:
- Greater intervention effects on health-related quality of life
SECONDARY OBJECTIVES:
- Greater intervention effects on patient activation II. Greater satisfaction with care and decision-making III. Greater documentation of goals of care and symptoms IV. To lower acute care V. Greater palliative care and hospice
OUTLINE: Sites are randomized to 1 of 2 arms.
ARM A: Patients receive educational materials to assist with advance care planning and symptom management through a technology-based supportive cancer care weekly during months 1-4 and every other week during months 5-12.
ARM B: Patients are paired with a lay health worker who will discuss the same educational materials from ARM A either in person or by telephone discussions weekly during months 1-4 and every other week during months 5-12.
All participants complete a baseline interview upon enrollment during the initial consent phone contact and then a survey at 3-, 6-and 12-months post enrollment.
Keywords
End of Life, Cancer, Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Stomach Neoplasms, Glioblastoma, Rectal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Skin Neoplasms, Small Cell Lung Carcinoma, Osteosarcoma, Myelodysplastic Syndromes, Disease Progression, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Urogenital Neoplasms, Carcinoma, Bronchogenic, Death, Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care
Eligibility
You can join if…
Open to people ages 21 years and up
- Newly diagnosed patients with a solid tumor cancer diagnosis or hematologic malignancy
- Patients must have the ability to understand and willingness to provide consent
- Participants must speak English or Spanish
You CAN'T join if...
- Inability to consent to the study
- Plans to change oncologist within 12 months
- Employed by the practice site
- Patients who anticipate moving from the area within 12 months
Locations
- Zuckerberg San Francisco General
not yet accepting patients
San Francisco California 94110 United States - San Francisco VA Medical Center
accepting new patients
San Francisco California 94121 United States - Kaiser Foundation Research Institute
not yet accepting patients
San Francisco California 94115 United States - University of San Francisco
not yet accepting patients
San Francisco California 94117 United States - VA Medical Center, Fresno
accepting new patients
Fresno California 93703 United States - Oncology Institute for Hope and Innovation
not yet accepting patients
Los Angeles California 90017 United States - St Jude Heritage Medical Group
not yet accepting patients
Fullerton California 92835 United States - Sacramento VA Medical Center - VA Northern California Health Care System
accepting new patients
Mather California 95655 United States - Beckman Research Institute of City of Hope
not yet accepting patients
Duarte California 91010 United States - VA Palo Alto
accepting new patients
Palo Alto California 94305 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Stanford University
- ID
- NCT05297734
- Study Type
- Interventional
- Participants
- Expecting 2996 study participants
- Last Updated